A clinical‑stage biotechnology company developing immunotherapies designed to overcome tumor resistance to cancer treatments. Its pipeline focuses on novel approaches that aim to restore immune system recognition of cancer cells, with several drug candidates evaluated in early‑ and mid‑stage clinica...
No congressional trades have been disclosed for TuHURA Biosciences, Inc. (TUBI) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
No congressional trades found for this stock.